Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 11/20 | 0.48 |
| ▸ | MTOR | P42345 | 9/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4436820 | 0.92 | MTOR (0.49) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL4439746 | 0.89 | PIK3CA (0.52) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL21054518 | 0.87 | PIK3CA (0.53) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL14034104 | 0.86 | NPY5R (0.57) | PIK3CAPIK3R1MTORPIKFYVENPY5R | |
| SCHEMBL466265 | 0.84 | PIK3CA (0.66) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL1862105 | 0.83 | MTOR (0.53) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL5105191 | 0.83 | PIK3CA (0.51) | PIK3CAPIK3R1MTORPIK3CGPIKFYVE | |
| SCHEMBL4441214 | 0.83 | PIK3CA (0.50) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL4433859 | 0.82 | JAK2 (0.43) | PIK3CAPIK3R1MTORPIKFYVESTK17B | |
| SCHEMBL5103147 | 0.82 | PIK3CA (0.53) | PIK3CAPIK3R1MTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487533-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2114950-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2114950-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885PIK3R1 16/4885MTOR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.